The increase put shareholders back in significantly positive territory, with returns of over 70% in the past year versus a 3% increase in the broader market.
Last month's rally came as a result of the biotech company announcing an agreement to be purchased by Roche Holdings (RHHBY 0.78%) for nearly $5 billion, or $114.50 per share. That price equates to a 122% premium over the stock's value on trading day prior to the deal's announcement.
Check out the latest earnings call transcript for Spark.
Spark Therapeutics shareholders should see their stock holdings convert to cash at that $114.50 price when the deal closes sometime in the second quarter of 2019. After that, the company will continue to operate as an independent group within Roche Holdings, but will benefit from its parent's global reach as it seeks to better commercialize treatments like its Luxturna genetic eye disease drug. That deal ensures positive returns for all shareholders, which counts as a solid win in the volatile biotech world.